Harding, James J.

Publications

Sort by

Co-Author Network

selected publications

Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib. Cancer medicine. 2020 Academic Article GET IT
Times cited: 8
Clinical implications of drug-induced liver injury in early-phase oncology clinical trials. Cancer. 2020 Academic Article GET IT
Times cited: 4
Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma. The oncologist. 2020 Academic Article GET IT
Times cited: 11
Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Academic Article GET IT
Times cited: 94
Characterization of on-target adverse events caused by TRK inhibitor therapy. Annals of oncology : official journal of the European Society for Medical Oncology. 2020 Academic Article GET IT
Times cited: 26
Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial. JAMA oncology. 2019 Academic Article GET IT
Times cited: 61
First-in-Humans Imaging with ⁸⁹Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2019 Academic Article GET IT
Times cited: 131
In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors. The Journal of clinical investigation. 2019 Academic Article GET IT
Times cited: 28
A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Academic Article GET IT
Times cited: 20
Binimetinib plus Gemcitabine and Cisplatin Phase I/II Trial in Patients with Advanced Biliary Cancers. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 21
Regional differences in gallbladder cancer pathogenesis: Insights from a multi-institutional comparison of tumor mutations. Cancer. 2018 Academic Article GET IT
Times cited: 34
A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies. Cancer chemotherapy and pharmacology. 2018 Academic Article GET IT
Times cited: 29
Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience. BMC cancer. 2018 Academic Article GET IT
Times cited: 56
Learning All That We Can From MyPathway. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Letter GET IT
Times cited: 1
Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Academic Article GET IT
Times cited: 132
Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 276
Immune checkpoint blockade in advanced hepatocellular carcinoma: an update and critical review of ongoing clinical trials. Future oncology (London, England). 2018 Review GET IT
Times cited: 23
HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018 Academic Article GET IT
Times cited: 473
In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of ¹⁸F-(2S,4R)-4-Fluoroglutamine. Radiology. 2018 Academic Article GET IT
Times cited: 66
Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma. Journal of the National Comprehensive Cancer Network : JNCCN. 2018 Academic Article GET IT
Times cited: 35
Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation. Oncotarget. 2017 Academic Article GET IT
Times cited: 7
Reply to: "Adjuvant Medications that Improve Survival after Locoregional Therapy". Journal of vascular and interventional radiology : JVIR. 2017 Letter GET IT
Times cited: 1
A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma. Cancer. 2017 Academic Article GET IT
Times cited: 54
Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature medicine. 2017 Academic Article GET IT
Times cited: 30
Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Academic Article GET IT
Times cited: 137
Adjuvant Medications That Improve Survival after Locoregional Therapy. Journal of vascular and interventional radiology : JVIR. 2017 Academic Article GET IT
Times cited: 9
OncoKB: A Precision Oncology Knowledge Base. JCO precision oncology. 2017 Academic Article GET IT
Times cited: 394
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature medicine. 2017 Academic Article GET IT
Times cited: 1922
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel. Investigational new drugs. 2017 Academic Article GET IT
Times cited: 10
Patient perspectives on ipilimumab across the melanoma treatment trajectory. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2017 Academic Article GET IT
Times cited: 12
Hepatocellular carcinoma in patients with HIV. Current opinion in HIV and AIDS. 2017 Review GET IT
Times cited: 15
Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference. Journal of gastrointestinal oncology. 2016 Academic Article GET IT
Times cited: 372
Combined intrahepatic cholangiocarcinoma and hepatocellular carcinoma. Chinese clinical oncology. 2016 Review GET IT
Times cited: 29
Advanced Hepatocellular Cancer: the Current State of Future Research. Current treatment options in oncology. 2016 Review GET IT
Times cited: 49
Acute myeloid leukemia masquerading as hepatocellular carcinoma. 2016 GET IT
Times cited: 322
Immunotherapy in hepatocellular carcinoma: Primed to make a difference?. Cancer. 2015 Review GET IT
Times cited: 105
A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases. The oncologist. 2015 Academic Article GET IT
Times cited: 54
Predicting responsiveness to sorafenib: can the determination of FGF3/FGF4 amplifications enrich for clinical benefit?. Hepatobiliary surgery and nutrition. 2014 Academic Article GET IT
Treating advanced hepatocellular carcinoma: How to get out of first gear. Cancer. 2014 Review GET IT
Times cited: 29
From the liver to the foot: a case of systemic embolism and acrometastasis in hepatocellular carcinoma. Gastrointestinal cancer research : GCR. 2014 Academic Article GET IT
Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies. 2014 GET IT
Times cited: 67
Cutis verticis gyrata in association with vemurafenib and whole-brain radiotherapy. 2014 GET IT
Times cited: 34
Systemic therapy for hepatocellular carcinoma. Chinese clinical oncology. 2013 Academic Article GET IT
Times cited: 5
Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer. 2013 Academic Article GET IT
Times cited: 150
Ipilimumab for patients with advanced mucosal melanoma. The oncologist. 2013 Academic Article GET IT
Times cited: 125
Progression of RAS-mutant leukemia during RAF inhibitor treatment. 2012 GET IT
Times cited: 197
Vemurafenib sensitivity skin reaction after ipilimumab. The New England journal of medicine. 2012 Letter GET IT
Times cited: 83
Causes and consequences of microRNA dysregulation. Cancer journal (Sudbury, Mass.). 2012 Review GET IT
Times cited: 228
Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma. Cancer journal (Sudbury, Mass.). 2012 Review GET IT
Times cited: 55

more ...

less ...

Background

education and training

M.D., Albert Einstein College of Medicine of Yeshiva University 2007
B.A., College of the Holy Cross 2000

Contact

full name

James J. Harding

VIVO Weill Cornell Medical College

James J. Harding Assistant Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name